J2KBIO（A420570）株式概要バイオベンチャーのJ2KBIO株式会社は、天然素材と微生物発酵から、化粧品、機能性食品、家庭用品の有効成分を提供している。 詳細A420570 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績4/6財務の健全性6/6配当金2/6報酬株価収益率（ 12.4 x）は、 Biotechs業界平均（ 26 x）を下回っています。過去1年間で収益は39.4%増加しました リスク分析過去5年間で収益は年間3%減少しました。 意味のある時価総額がありません ( ₩50B )すべてのリスクチェックを見るA420570 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW491,196 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG491,196 investors already sharing narrativesYour Fair Value₩Current Price₩8.51k40.5% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-312m37b2016201920222025202620282031Revenue ₩36.8bEarnings ₩4.0bAdvancedSet Fair ValueView all narrativesJ2KBIO Co., Ltd. 競合他社GeneBioTech LtdSymbol: KOSDAQ:A086060Market cap: ₩36.8bSeoulin BioscienceLtdSymbol: KOSDAQ:A038070Market cap: ₩39.1bBIO-FD&CLtdSymbol: KOSDAQ:A251120Market cap: ₩71.8bPanGen BiotechSymbol: KOSDAQ:A222110Market cap: ₩66.0b価格と性能株価の高値、安値、推移の概要J2KBIO過去の株価現在の株価₩8,510.0052週高値₩11,850.0052週安値₩6,710.00ベータ0.431ヶ月の変化6.64%3ヶ月変化11.39%1年変化-16.40%3年間の変化n/a5年間の変化n/aIPOからの変化-67.27%最新ニュースValuation Update With 7 Day Price Move • 19hInvestor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,510, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 14% over the past year.Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 7.0% to ₩8,050. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 19%.Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,790, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 16% over the past year.Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,390, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total loss to shareholders of 11% over the past year.Buy Or Sell Opportunity • Apr 09Now 20% overvaluedOver the last 90 days, the stock has fallen 6.7% to ₩7,710. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 11% to ₩7,750. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • 19hInvestor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,510, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 14% over the past year.Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 7.0% to ₩8,050. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 19%.Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,790, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 16% over the past year.Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,390, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total loss to shareholders of 11% over the past year.Buy Or Sell Opportunity • Apr 09Now 20% overvaluedOver the last 90 days, the stock has fallen 6.7% to ₩7,710. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 11% to ₩7,750. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Mar 05Now 22% overvaluedOver the last 90 days, the stock has fallen 7.1% to ₩7,800. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.お知らせ • Feb 13J2KBIO Co., Ltd., Annual General Meeting, Mar 27, 2026J2KBIO Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 50-3, dureungyuri-ro, ochang-eup, cheongwon-gu, chungcheongbuk-do, cheongju South Korea分析記事 • Dec 17J2KBIO Co., Ltd.'s (KOSDAQ:420570) Prospects Need A Boost To Lift SharesJ2KBIO Co., Ltd.'s ( KOSDAQ:420570 ) price-to-sales (or "P/S") ratio of 1.8x might make it look like a strong buy right...Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,720, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 3.8% over the past year.Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ₩143 (vs ₩45.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩143 (up from ₩45.00 loss in 3Q 2024). Revenue: ₩8.56b (up 32% from 3Q 2024). Net income: ₩838.4m (up ₩1.09b from 3Q 2024). Profit margin: 9.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue.New Risk • Apr 13New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.8% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 25% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩65.2b market cap, or US$46.0m).Reported Earnings • Mar 30Full year 2024 earnings released: ₩299 loss per share (vs ₩1,001 profit in FY 2023)Full year 2024 results: ₩299 loss per share (down from ₩1,001 profit in FY 2023). Revenue: ₩33.1b (up 16% from FY 2023). Net loss: ₩1.65b (down 134% from profit in FY 2023).分析記事 • Feb 27A Piece Of The Puzzle Missing From J2KBIO Co., Ltd.'s (KOSDAQ:420570) 28% Share Price ClimbJ2KBIO Co., Ltd. ( KOSDAQ:420570 ) shareholders have had their patience rewarded with a 28% share price jump in the...分析記事 • Feb 27J2KBIO Co., Ltd.'s (KOSDAQ:420570) Shares Leap 28% Yet They're Still Not Telling The Full StoryThe J2KBIO Co., Ltd. ( KOSDAQ:420570 ) share price has done very well over the last month, posting an excellent gain of...New Risk • Feb 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩66.1b market cap, or US$45.9m).お知らせ • Feb 15J2KBIO Co., Ltd., Annual General Meeting, Mar 28, 2025J2KBIO Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 50-3, dureungyuri-ro, ochang-eup, cheongwon-gu, chungcheongbuk-do, cheongju South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩55.0b market cap, or US$38.3m).Reported Earnings • Nov 12Third quarter 2024 earnings released: ₩45.00 loss per share (vs ₩283 profit in 3Q 2023)Third quarter 2024 results: ₩45.00 loss per share (down from ₩283 profit in 3Q 2023). Revenue: ₩6.51b (down 16% from 3Q 2023). Net loss: ₩250.3m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 36% growth forecast for the Biotechs industry in South Korea.Buy Or Sell Opportunity • Nov 08Now 24% overvaluedOver the last 90 days, the stock has fallen 28% to ₩13,270. The fair value is estimated to be ₩10,718, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 70% over the last year. Earnings per share has declined by 73%.Valuation Update With 7 Day Price Move • Oct 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩13,810, the stock trades at a trailing P/E ratio of 78.2x. Average forward P/E is 23x in the Biotechs industry in South Korea.分析記事 • Aug 23J2KBIO (KOSDAQ:420570) Has A Rock Solid Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Buy Or Sell Opportunity • Aug 02Now 21% undervaluedOver the last 90 days, the stock has risen 5.9% to ₩18,900. The fair value is estimated to be ₩23,836, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 73% over the last year. Meanwhile, the company became loss making.New Risk • Jun 27New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.5b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risk Market cap is less than US$100m (₩135.5b market cap, or US$97.9m).Valuation Update With 7 Day Price Move • May 10Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩22,600, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 23x in the Biotechs industry in South Korea.Buy Or Sell Opportunity • May 10Now 23% overvaluedThe stock has been flat over the last 90 days, currently trading at ₩22,600. The fair value is estimated to be ₩18,317, however this is not to be taken as a sell recommendation but rather should be used as a guide only.Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩16,340, the stock trades at a trailing P/E ratio of 18.8x. Average trailing P/E is 21x in the Biotechs industry in South Korea.株主還元A420570KR BiotechsKR 市場7D17.2%-1.3%-13.8%1Y-16.4%4.4%130.8%株主還元を見る業界別リターン: A420570過去 1 年間で4.4 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A420570は、過去 1 年間で130.8 % のリターンを上げたKR市場を下回りました。価格変動Is A420570's price volatile compared to industry and market?A420570 volatilityA420570 Average Weekly Movement9.6%Biotechs Industry Average Movement11.0%Market Average Movement9.3%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%安定した株価: A420570 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A420570の 週次ボラティリティ ( 10% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201454Jaeseop Leewww.j2kbio.comバイオベンチャーのJ2KBIO株式会社は、天然素材と微生物発酵から化粧品、機能性食品、家庭用品の有効成分を提供している。同社は2014年に設立され、韓国の清州市に拠点を置いている。もっと見るJ2KBIO Co., Ltd. 基礎のまとめJ2KBIO の収益と売上を時価総額と比較するとどうか。A420570 基礎統計学時価総額₩49.76b収益（TTM）₩4.03b売上高(TTM)₩36.82b12.4xPER（株価収益率1.4xP/SレシオA420570 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A420570 損益計算書（TTM）収益₩36.82b売上原価₩22.14b売上総利益₩14.68bその他の費用₩10.65b収益₩4.03b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）688.96グロス・マージン39.86%純利益率10.94%有利子負債／自己資本比率1.2%A420570 の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.9%現在の配当利回りn/a配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/02 04:47終値2026/07/02 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋J2KBIO Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • 19hInvestor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,510, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 14% over the past year.
Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 7.0% to ₩8,050. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 19%.
Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,790, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 16% over the past year.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,390, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total loss to shareholders of 11% over the past year.
Buy Or Sell Opportunity • Apr 09Now 20% overvaluedOver the last 90 days, the stock has fallen 6.7% to ₩7,710. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 11% to ₩7,750. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.
Valuation Update With 7 Day Price Move • 19hInvestor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,510, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 14% over the past year.
Buy Or Sell Opportunity • Jul 01Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 7.0% to ₩8,050. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 19%.
Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,790, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 32x in the Biotechs industry in South Korea. Total loss to shareholders of 16% over the past year.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,390, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total loss to shareholders of 11% over the past year.
Buy Or Sell Opportunity • Apr 09Now 20% overvaluedOver the last 90 days, the stock has fallen 6.7% to ₩7,710. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 11% to ₩7,750. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Mar 05Now 22% overvaluedOver the last 90 days, the stock has fallen 7.1% to ₩7,800. The fair value is estimated to be ₩6,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company has become profitable.
お知らせ • Feb 13J2KBIO Co., Ltd., Annual General Meeting, Mar 27, 2026J2KBIO Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 50-3, dureungyuri-ro, ochang-eup, cheongwon-gu, chungcheongbuk-do, cheongju South Korea
分析記事 • Dec 17J2KBIO Co., Ltd.'s (KOSDAQ:420570) Prospects Need A Boost To Lift SharesJ2KBIO Co., Ltd.'s ( KOSDAQ:420570 ) price-to-sales (or "P/S") ratio of 1.8x might make it look like a strong buy right...
Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,720, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 3.8% over the past year.
Reported Earnings • Nov 13Third quarter 2025 earnings released: EPS: ₩143 (vs ₩45.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩143 (up from ₩45.00 loss in 3Q 2024). Revenue: ₩8.56b (up 32% from 3Q 2024). Net income: ₩838.4m (up ₩1.09b from 3Q 2024). Profit margin: 9.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue.
New Risk • Apr 13New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.8% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 25% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩65.2b market cap, or US$46.0m).
Reported Earnings • Mar 30Full year 2024 earnings released: ₩299 loss per share (vs ₩1,001 profit in FY 2023)Full year 2024 results: ₩299 loss per share (down from ₩1,001 profit in FY 2023). Revenue: ₩33.1b (up 16% from FY 2023). Net loss: ₩1.65b (down 134% from profit in FY 2023).
分析記事 • Feb 27A Piece Of The Puzzle Missing From J2KBIO Co., Ltd.'s (KOSDAQ:420570) 28% Share Price ClimbJ2KBIO Co., Ltd. ( KOSDAQ:420570 ) shareholders have had their patience rewarded with a 28% share price jump in the...
分析記事 • Feb 27J2KBIO Co., Ltd.'s (KOSDAQ:420570) Shares Leap 28% Yet They're Still Not Telling The Full StoryThe J2KBIO Co., Ltd. ( KOSDAQ:420570 ) share price has done very well over the last month, posting an excellent gain of...
New Risk • Feb 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩66.1b market cap, or US$45.9m).
お知らせ • Feb 15J2KBIO Co., Ltd., Annual General Meeting, Mar 28, 2025J2KBIO Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 50-3, dureungyuri-ro, ochang-eup, cheongwon-gu, chungcheongbuk-do, cheongju South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩55.0b market cap, or US$38.3m).
Reported Earnings • Nov 12Third quarter 2024 earnings released: ₩45.00 loss per share (vs ₩283 profit in 3Q 2023)Third quarter 2024 results: ₩45.00 loss per share (down from ₩283 profit in 3Q 2023). Revenue: ₩6.51b (down 16% from 3Q 2023). Net loss: ₩250.3m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 36% growth forecast for the Biotechs industry in South Korea.
Buy Or Sell Opportunity • Nov 08Now 24% overvaluedOver the last 90 days, the stock has fallen 28% to ₩13,270. The fair value is estimated to be ₩10,718, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 70% over the last year. Earnings per share has declined by 73%.
Valuation Update With 7 Day Price Move • Oct 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩13,810, the stock trades at a trailing P/E ratio of 78.2x. Average forward P/E is 23x in the Biotechs industry in South Korea.
分析記事 • Aug 23J2KBIO (KOSDAQ:420570) Has A Rock Solid Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Buy Or Sell Opportunity • Aug 02Now 21% undervaluedOver the last 90 days, the stock has risen 5.9% to ₩18,900. The fair value is estimated to be ₩23,836, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 73% over the last year. Meanwhile, the company became loss making.
New Risk • Jun 27New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.5b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risk Market cap is less than US$100m (₩135.5b market cap, or US$97.9m).
Valuation Update With 7 Day Price Move • May 10Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩22,600, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 23x in the Biotechs industry in South Korea.
Buy Or Sell Opportunity • May 10Now 23% overvaluedThe stock has been flat over the last 90 days, currently trading at ₩22,600. The fair value is estimated to be ₩18,317, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩16,340, the stock trades at a trailing P/E ratio of 18.8x. Average trailing P/E is 21x in the Biotechs industry in South Korea.
